HIV-1 Ribonuclease H: Structure, Catalytic Mechanism and Inhibitors
Open accessThe DOI matches its Crossref record; 107 of the 108 references it cites were found in a registry or an index.
Abstract
Since the human immunodeficiency virus (HIV) was discovered as the etiological agent of acquired immunodeficiency syndrome (AIDS), it has encouraged much research into antiviral compounds. The reverse transcriptase (RT) of HIV has been a main target for antiviral drugs. However, all drugs developed so far inhibit the polymerase function of the enzyme, while none of the approved antiviral agents inhibit specifically the necessary ribonuclease H (RNase H) function of RT. This review provides a background on structure-function relationships of HIV-1 RNase H, as well as an outline of current attempts to develop novel, potent chemotherapeutics against a difficult drug target.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![Figure 2. A Crystal structure of HIV-1 RT (PDB code: 1RTD. The p51 subunit is shown in orange, while the p66 subunit is divided into the fingers (cyan), connection (blue) and RNase H (grey) subdomains. The residues of the conserved DEDD motif are shown and red and marked with arrows. B Crystal structures of the RNase H domain of HIV-1 RT (PDB code:1RTD) [5], human RNase H1 (PDB code: 2QKB) [12] and E. coli RNase H1 (PBD code: 1WSJ). All three show the same mixed beta-sheet with asymmetric alpha helices, while the human and E. coli RNases H contain the C-helix, or basic loop.](https://figures.cochat.ai/paper-figures/b63df9a426c04092bf0ff917330c098e/hiv-1-ribonuclease-h-structure-catalytic-mechanism-and-inhibitors-figure-2.jpg)



![Figure 6. A During (−)-strand DNA synthesis, the PPT region of the RNA genome is resistant to RNase H cleavage, while a portion of the RNA genome is degraded concomitantly with (−)-strand DNA synthesis. Here, a specific cleavage is made to create the PPT primer. B The RNase H-resistant PPT sequence forms the primer for (+)-strand DNA synthesis when the rest of the genome is completely degraded by RNase H. C The RNA primer is extended 12 nucleotides, D then RT pauses and changes orientations to a polymerase-independent binding mode in order to cleave at the DNA:RNA junction, and remove the PPT primer. E The 12-mer fragment is extended toward the 5′ end of the (−)-strand DNA (see Figure 1F). After the second strand transfer event, the (+)-strand DNA is fully synthesized resulting in a fully double-stranded provirus. Adapted from [49].](https://figures.cochat.ai/paper-figures/20a118ca091245829bbec2fa00a9968d/hiv-1-ribonuclease-h-structure-catalytic-mechanism-and-inhibitors-figure-6.jpg)
![Figure 7. Examples of the main classes of small molecule inhibitors against HIV-1 RT-associated RNase H activity. A N-hydroxyimides. Developed from influenza inhibitors and among the first to use the 3-oxygen pharmacophore [84]. B Pyrimidinol carboxylic acid derivatives [85]. Potent inhibitors based on the successful scaffold of the metal-chelating active site inhibitors. C Diketo acid derivatives are also active in some cases against the viral integrase. RDS1643 shown here is the only diketo acid to have antiviral activity in vivo [86]. D The vinylogous ureas (NSC727447 pictured here) represent a different kind of inhibitor that binds allosterically near the p51 thumb [87]. E N-acyl hydrazones appear to bind to multiple binding sites depending on the specific inhibitor, including the RNase H domain and a site that overlaps the NNRTI binding pocket (DHBNH picture above) [88]. F Hydroxylated tropolones (β-thujaplicinol pictured here) are the subject of several studies that have provided the basis for a biochemical mechanism of inhibition by active site RNase H inhibitors [39,89,90].](https://figures.cochat.ai/paper-figures/3e3e02f115734f71b03c1cf5be0d88d9/hiv-1-ribonuclease-h-structure-catalytic-mechanism-and-inhibitors-figure-7.jpg)
![Figure 8. A schematic of possible models of active site inhibitor binding, based on studies with the tropolone derivative β-thujaplicinol (blue sphere) [39,90]. Evidence suggests that the inhibitor is unable to bind to an enzyme-substrate (E-S) complex (top left), only to free enzyme forming (top right) and enzyme-inhibitor (E-I) complex (bottom right). However, the substrate might be able to bind to this E-I complex, forming an E-S-I complex that is not productive with respect to RNase H cleavage (bottom left). As suggested by Himmel et al., the inhibitor occupies the position normally claimed by the scissile phosphate [90]. As such, it is possible that the substrate undergoes a change in trajectory in relation to the scissile phosphate and the RNase H active site [39]. Then eventually, the inhibitor dissociates and RT is allowed to cleave the uninhibited substrate (E-S complex, top left).](https://figures.cochat.ai/paper-figures/1c9b6865dd434338935d8adfac6655d4/hiv-1-ribonuclease-h-structure-catalytic-mechanism-and-inhibitors-figure-8.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Based on these structural and functional experiments, the two metal-binding mechanism has been widely accepted [27,28,30,31,63,64].”
From Retroviral RNase H: structure, mechanism, and inhibition (2021) · cites this paper as [30]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor
Kohlstaedt, L. A., Wang, J., Friedman, J. M., Rice, P. A., & Steitz, T. A. (1992) · Science · doi:10.1126/science.1377403 · Cited by 1,914 · cited 1×
“the non-nucleoside binding pocket, a hydrophobic depression created by the binding of non-nucleoside reverse transcriptase inhibitors (NNRTIs) and located near the base of the p66 thumb subdomain, about 10 Å from the polymerase active site [4,64,65].”
BackgroundHuang, H., Chopra, R., Verdine, G. L., & Harrison, S. C. (1998) · Science · doi:10.1126/science.282.5394.1669 · Cited by 1,420
Inhibitors of Strand Transfer That Prevent Integration and Inhibit HIV-1 Replication in Cells
Hazuda, D. J., Felock, P., Witmer, M., Wolfe, A., Stillmock, K., Grobler, J. A., Espeseth, A., Gabryelski, L., Schleif, W., Blau, C., et al. (2000) · Science · doi:10.1126/science.287.5453.646 · Cited by 1,131 · cited 1×
“Diketo acids also form a group of compounds initially developed against the structurally similar HIV-1 integrase (IN) [92,93].”
BackgroundJacobo-Molina, A., Ding, J., Nanni, R. G., Clark, A. D., Lu, X., Tantillo, C., Williams, R. L., Kamer, G., Ferris, A. L., Clark, P., et al. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.13.6320 · Cited by 1,115 · cited 2×
“B-form geometry near the RNase H active site [6].”
BackgroundAnti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV.
De Clercq, E. (2009) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2008.10.010 · Cited by 627 · cited 2×
“There are currently 25 compounds in clinical use to treat HIV [2].”
BackgroundNowotny, M., Gaidamakov, S. A., Crouch, R. J., & Yang, W. (2005) · Cell · doi:10.1016/j.cell.2005.04.024 · Cited by 620 · cited 3×
“halodurans ) [9-11] and eukaryotic (human) [12] RNases H, and is part of the superfamily of polynucleotidyl transferases.”
BackgroundMaking and Breaking Nucleic Acids: Two-Mg2+-Ion Catalysis and Substrate Specificity
Yang, W., Lee, J. Y., & Nowotny, M. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.03.013 · Cited by 573 · cited 1×
“This has led to the general acceptance of a two-metal ion mechanism for retroviral RNase H hydrolysis [11,12,17].”
BackgroundCrystal structure of the ribonuclease H domain of HIV-1 reverse transcriptase
Davies, J. F., Hostomska, Z., Hostomsky, Z., Jordan, S. R., & Matthews, D. A. (1991) · Science · doi:10.1126/science.1707186 · Cited by 570 · cited 2×
“In the case of HIV-1 RT, the RNase H domain constitutes the C-terminus of the p66 subunit, which is missing in p51, due to cleavage by the viral protease [3-7].”
BackgroundHigh resolution structures of HIV-1 RT from four RT–inhibitor complexes
Ren, J., Esnouf, R., Garman, E., Somers, D., Ross, C., Kirby, I., Keeling, J., Darby, G., Jones, Y., Stuart, D., et al. (1995) · Nature Structural & Molecular Biology · doi:10.1038/nsb0495-293 · Cited by 502 · cited 1×
“the non-nucleoside binding pocket, a hydrophobic depression created by the binding of non-nucleoside reverse transcriptase inhibitors (NNRTIs) and located near the base of the p66 thumb subdomain, about 10 Å from the polymerase active site [4,64,65].”
BackgroundMechanism and fidelity of HIV reverse transcriptase.
Kati, W. M., Johnson, K. A., Jerva, L. F., & Anderson, K. S. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)35706-5 · Cited by 492 · cited 1×
“In the presence of deoxyribonucleotides (dNTPs) RT will advance and RNase H will eventually continue to cut the template; however, the rate of RNase H cleavage is approximately seven times slower than polymerization [33].”
Background
Research works printed but not linked: 1
- Telesnitsky, A., and Goff, S. (1997). Cold Spring Harbor Laboratory Press.
Cited by
Menéndez-Arias, L. (2013) · Antiviral Research · doi:10.1016/j.antiviral.2013.01.007 · Cited by 207
RNases H: Structure and mechanism
Hyjek, M., Figiel, M., & Nowotny, M. (2019) · DNA Repair · doi:10.1016/j.dnarep.2019.102672 · Cited by 160
Vernekar, S. K. V., Liu, Z., Nagy, E., Miller, L., Kirby, K. A., Wilson, D. J., Kankanala, J., Sarafianos, S. G., Parniak, M. A., & Wang, Z. (2015) · Journal of Medicinal Chemistry · doi:10.1021/jm501132s · Cited by 137
Menéndez-Arias, L., Sebastián-Martín, A., & Álvarez, M. (2017) · Virus Research · doi:10.1016/j.virusres.2016.12.019 · Cited by 123
Esposito, F., Corona, A., & Tramontano, E. (2012) · Molecular Biology International · doi:10.1155/2012/586401 · Cited by 138
“This action occurs through the deprotonation of a water molecule, with the production of a nucleophilic hydroxide group that attacks the scissile phosphate group on the RNA previously activated by coordination with the Mg cofactor [24].”
Background
Metadata
- Authors
- Beilhartz, G. L., & Götte, M.
- Affiliations
- McGill University (CA)
- Corresponding author
- Götte, Matthias
- Venue
- Viruses
- Publisher
- MDPI AG
- Published
- 2010-03-30
- Volume
- 2
- Issue
- 4
- Pages
- 900-926
- ISSN
- 1999-4915 (ISSN-L)
- PMC
- PMC3185654
- OpenAlex
- W2025259834
- Cited by
- 88
- References
- 108
- Citations by year
- 2026: 6 · 2025: 1 · 2024: 6 · 2023: 4 · 2022: 7 · 2021: 8 · 2020: 4 · 2019: 6 · 2018: 7 · 2017: 8 · 2016: 6 · 2015: 2 · 2014: 3 · 2013: 6 · 2012: 8
- FWCI
- 4.15
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Viruses (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › HIV/AIDS drug development and treatment
- Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Structural Biology › Enzyme Structure and Function
- Keywords
- HIV-1, RNase H, reverse transcriptase, catalytic mechanism, enzyme structure, structure-function relationship, RNase H inhibitors, antiviral drug discovery
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: HIV-1 Ribonuclease H: Structure, Catalytic Mechanism and Inhibitors. https://app.cochat.ai/papers/10.3390/v2040900
- The paper
- Beilhartz, G. L., & Götte, M. (2010). HIV-1 Ribonuclease H: Structure, Catalytic Mechanism and Inhibitors. Viruses. https://doi.org/10.3390/v2040900
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.